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Abstract
Following a request from the European Commission, the EFSA Panel on Additives and Products or
Substances used in Animal Feed was asked to deliver a scientiﬁc opinion on the safety and efﬁcacy of
B-Act® when used in feed for turkeys for fattening, reared for breeding and minor poultry species for
fattening or raised for laying. B-Act® is a preparation containing viable spores of a Bacillus licheniformis
strain. This species is considered by EFSA to be suitable for the qualiﬁed presumption of safety (QPS)
approach to safety assessment, which requires the identity of the strain to be established and evidence
that it is not toxigenic and does not show acquired resistance to relevant antibiotics. In a previous
opinion, the strain was found to meet the criteria for the QPS approach. Since no concerns are expected
from other components of the additive, B-Act® is presumed safe for the target species, consumers and
the environment. In the same opinion, no conclusions could be drawn on the skin/eye irritation or skin
sensitisation potential of the additive, but B-Act® was considered a potential respiratory sensitiser. Since
the use of B-Act® with the target species is considered unlikely to introduce hazards for users of the
product not already considered, the conclusions previously reached apply to the current application.
B-Act® at the recommended dose of 1.6 9 109 colony forming units (CFU)/kg feed has the potential to
be efﬁcacious in turkeys for fattening. Since the same dose is proposed for the minor poultry species for
fattening or raised for laying, the conclusions can be extended/extrapolated to these species. The
conclusions on the compatibility of B-Act® with coccidiostats previously drawn apply to the current
application provided that the maximum authorised concentrations of the coccidiostats for the target
species are equal/lower than those for chickens.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from HuvePharma NV2 for authorisation of the
product B-Act® (Bacillus licheniformis DSM 28710) when used as a feed additive for turkeys for
fattening, turkeys reared for breeding and minor poultry species (category: zootechnical additives;
functional group: gut ﬂora stabilisers). In the course of the assessment the applicant clariﬁed that the
minor poultry species were for fattening and rearing.3
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the
applicant the technical dossier in support of this application. The particulars and documents in support
of the application were considered valid by EFSA as of 2 August 2017.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of B-Act®
(Bacillus licheniformis DSM 28710), when used under the proposed conditions of use (see
Section 3.1.2).
1.2. Additional information
The additive B-Act® is a preparation containing viable spores of B. licheniformis DSM 28710. EFSA
has issued an opinion on the safety and efﬁcacy of this product when used with chickens for fattening
and reared for laying (EFSA FEEDAP Panel, 2016).
The additive is currently authorised for use as a zootechnical feed additive (gut ﬂora stabiliser) in
feed for chickens for fattening and chickens reared for laying.4
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier5 in support of the authorisation request for the use of B-Act® (Bacillus licheniformis DSM
28710) as a feed additive.
The European Union Reference Laboratory (EURL) considered that the conclusions and
recommendations reached in the previous assessment are valid and applicable for the current
application.6
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of B-Act® (Bacillus
licheniformis DSM 28710) is in line with the principles laid down in Regulation (EC) No 429/2008 and
the relevant guidance documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012) and
Technical guidance on tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011).
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 HuvePharma NV, Uitbreidingstraat 80, 2600, Antwerp, Belgium.
3 Technical dossier/Supplementary information July 2018/EFSA letter ListDoc.
4 Commission Implementing Regulation (EU) 2017/1904 of 18 October 2017 concerning the authorisation of a preparation of
Bacillus licheniformis DSM 28710 as a feed additive for chickens for fattening and chickens reared for laying. OJ L 269,
19.10.2017, p. 27.
5 FEED dossier reference: FAD-2017-0034.
6 The full report is available on the EURL website: https://ec.europa.eu/jrc/en/eurl/feed-additives/evaluation-reports/fad-2015-
0016?search&form-return
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3. Assessment
B-Act® is a preparation of viable spores of a single strain of B. licheniformis intended for use as a
zootechnical additive (gut ﬂora stabiliser) in feeds for turkeys for fattening, turkeys reared for breeding
and minor poultry species for fattening or raised for laying to improve their performance.
3.1. Characterisation
3.1.1. Characterisation of the additive
B-Act® is a powder with a minimum declared content of 3.2 9 109 colony forming units (CFU) of B.
licheniformis DSM 287107 per gram of additive. It has the same formulation (spores concentrate, ~ 3%
and calcium carbonate, ~ 97%) and method of manufacture as that considered in a previous
application (EFSA FEEDAP Panel, 2016). Thus, the data pertaining to composition, impurities, physical
properties and shelf life still apply.
The stability and capacity of the additive to homogeneously mix with poultry feed and premixtures
were established in the previous opinion (EFSA FEEDAP Panel, 2016). The FEEDAP Panel is of the
opinion that these existing data are sufﬁcient to establish the stability and capacity to homogeneously
mix of the additive in premixtures and feeds for the target species.
3.1.2. Conditions of use
The additive B-Act® is intended for use in feed for turkeys for fattening, turkeys reared for
breeding and minor growing species for fattening or raised for laying at the proposed dose of 1.6 9
109 CFU/kg complete feedingstuffs.
It is intended for use in the presence of the permitted coccidiostats: salinomycin, lasalocid, robenidine,
maduramicin, decoquinate, monensin, narasin, nicarbazin, semduramicin, diclazuril and halofuginone.
3.2. Safety
3.2.1. Safety for the target species, consumers and environment
The species B. licheniformis is considered by EFSA to be suitable for the qualiﬁed presumption of
safety (QPS) approach to safety assessment (EFSA, 2007, EFSA BIOHAZ Panel, 2017). This approach
requires the identity of the strain to be conclusively established and evidence that it lacks of toxigenic
potential and does not show resistance to antibiotics of human and veterinary importance. In a previous
opinion on the use of the additive with chickens for fattening (EFSA FEEDAP Panel, 2016), the
identiﬁcation of the strain and compliance with the QPS qualiﬁcations were conﬁrmed. Therefore, B.
licheniformis DSM 28710 was presumed safe for the target animals, consumers of products derived
from the animals fed the additive and the environment. Since no concerns arise from other components
of the additive, B-Act® is also presumed safe for the target animals, consumers and the environment.
3.2.2. Safety for the user
In the previous opinion, owing to the absence of data, no conclusions could be drawn on the skin/
eye irritation or skin sensitisation potential of the additive, but the Panel considered B-Act® to be a
potential respiratory sensitiser (EFSA FEEDAP Panel, 2016). No additional studies were provided in the
current application. The use of the additive with turkeys for fattening, turkeys reared for breeding and
minor growing poultry species is considered unlikely to introduce hazards for users of the product not
already considered as part of the ﬁrst assessment. Therefore, the conclusions reached in the previous
assessment apply to the current application.
7 The applicant uses BL11 as in-house identiﬁer.
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3.3. Efﬁcacy
3.3.1. Efﬁcacy for turkeys for fattening
Five ﬂoor pen studies conducted in three Member States with fattening turkeys were performed to
demonstrate the efﬁcacy of the product. However, one study8 was not considered adequate to support
the efﬁcacy of the additive due to the low and extremely variable performance of the animals9;
therefore, it was disregarded.
The detailed design of the remaining four studies is presented in Table 1 and the results in Table 2.
They were ﬂoor pen studies with one-day-old turkeys (females in studies 1, 2 and 4, and males in
study 3) randomly allocated to two treatment groups (control and B-Act® at the recommended dose),
and fed their respective diets ad libitum during the whole experimental period. Three or four phase-
diets were used. Concentration of the additive in feed was conﬁrmed by analysis. In all studies, the
health status of birds was monitored throughout the experimental periods. In the ﬁrst study, birds that
died within the ﬁrst week were replaced. Feed intake and body weight of the animals were measured
at diet change and the feed to gain ratio was calculated. Data were analysed using one-way analysis
of variance (ANOVA), then mean groups were compared with the Duncan or Tukey’s test. The pen was
the experimental unit for all parameters.
Table 1: Details on the study design for the studies performed in turkeys
Study
Duration of
the study
(days)
Breed (sex)
Total animals
Replicates/
treatment 3
animals/
replicate
B-Act®
(CFU/kg
feed)
Basal diets (main
ingredients)
Diet form
1(1) 98 Hybrid converter
♀
612
18 9 17
0
1.6 9 109
Wheat/soybean meal mash
2(2) 84 Hybrid converter
♀
1,300
13 9 50
0
1.6 9 109
Wheat/barley/rye/triticale/
soybean meal pelleted
3(3) 84 Hybrid converter
♂
600
30 9 10
0
1.6 9 109
Wheat/soybean meal pelleted
4(4) 84 BUT premium
♀
240
12 9 10
0
1.6 9 109
Wheat/soybean meal/rye mash
and pelleted
CFU: colony forming unit.
(1): Technical dossier/Section IV/Annex IV.02.
(2): Technical dossier/Supplementary information July 2018/Annex IV_03.
(3): Technical dossier/Supplementary information July 2018/Annex IV_04.
(4): Technical dossier/Supplementary information July 2018/Annex IV_05.
Table 2: Summary of the overall performance results of the trials made with turkeys for fattening
Trial no
B-Act®
(CFU/kg feed)
Feed
intake (g)(1)
Weight
(kg)(2)
Average daily
weight gain
(g/day)
Feed:gain
Dead and
culled (%)
1 0 218.0 8.66 87.8 2.36a 9.4
1.6 9 109 213.7 8.73 88.4 2.31b 7.6
2 0 228.2 7.96b 94.0b 2.38a 4.9
1.6 9 109 227.8 8.12a 95.9a 2.34b 4.1
3 0 21,503b 10.47b n.r. 2.07 2.0
1.6 9 109 22,697a 10.93a n.r. 2.08 1.3
8 Technical dossier/Section IV/Annex IV.01.
9 Birds (BUT big 6, males) showed a daily weight gain at 84 days of life of 71.6 and 76.5 g/day in the control and treated
groups respectively, and an individual bodyweight ranging from 4 to 8.7 kg.
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Mortality was not treatment related. The supplementation of B-Act® at the minimum recommended
dose signiﬁcantly increased the weight of turkeys in two of the studies (2 and 3) and signiﬁcantly
improved the feed to gain ratio in three of the four studies.
Conclusions on efﬁcacy for turkeys for fattening
The FEEDAP Panel concludes that B-Act® at the minimum recommended dose of 1.6 9 109 CFU/kg
complete feedingstuffs has the potential to improve the performance of turkeys for fattening.
3.3.2. Efﬁcacy for turkeys reared for breeding and minor poultry species for
fattening or raised for laying
The efﬁcacy for turkeys for fattening was established in the studies described above and that for
chickens for fattening was established in a previous opinion (EFSA FEEDAP Panel, 2016). Since the
applicant proposes the use of the same dose (1.6 9 109 CFU/kg complete feedingstuffs) with turkeys
reared for breeding and minor poultry species for fattening or raised for laying, the conclusions
reached in turkeys and chickens for fattening can be extended/extrapolated to these poultry species/
categories.
3.3.3. Compatibility with coccidiostats
In the previous opinion on the use of B-Act® in feed for chickens for fattening and reared for
laying, the compatibility of B. licheniformis DSM 28710 with the coccidiostats salinomycin, lasalocid,
robenidine, maduramicin, decoquinate, monensin, narasin, nicarbazin, semduramicin, diclazuril and
halofuginone at the highest authorised levels for chickens for fattening was established (EFSA FEEDAP
Panel, 2016). Conclusions previously drawn apply to the current application provided that the
maximum authorised concentration of the coccidiostats for turkeys for fattening, turkeys reared for
breeding and minor growing poultry species (when maximum authorised concentrations exist), are
equal or lower than those for chickens for fattening.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation10 and Good
Manufacturing Practice.
4. Conclusions
The active agent fulﬁls the requirements of the QPS approach to the assessment of safety and no
concerns are expected from other components of the additive. Consequently, B-Act® can be presumed
to be safe for the target animals, consumers of products from treated animals and the environment.
In the absence of data, no conclusions could be drawn on the skin/eye irritation or skin
sensitisation potential of the additive, but B-Act® is considered a potential respiratory sensitiser.
B-Act® at the recommended dose of 1.6 9 109 CFU/kg feed has the potential to be efﬁcacious in
turkeys for fattening. Since the applicant proposes the use of the same dose (1.6 9 109 CFU/kg
complete feedingstuffs) with turkeys reared for breeding and minor poultry species for fattening or
raised for laying, the conclusions reached in turkeys for fattening and previously in chickens for
fattening can be extended/extrapolated to these poultry species/categories.
Trial no
B-Act®
(CFU/kg feed)
Feed
intake (g)(1)
Weight
(kg)(2)
Average daily
weight gain
(g/day)
Feed:gain
Dead and
culled (%)
4 0 161.0 6.28 74.1 2.17a 0
1.6 9 109 149.6 6.30 74.4 2.00b 1.7
CFU: colony forming unit; n.r.: not reported.
a,b: Means within a column with different superscript letters are signiﬁcantly different at p < 0.05.
(1): Average daily feed intake per bird in studies 1, 2 and 4 and total feed intake per bird in study 3.
(2): Final weight in studies 1, 2 and 4 and total weight gain in study 3.
10 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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In the previous opinion on the use of B-Act® in feed for chickens for fattening and reared for
laying, the compatibility of B. licheniformis DSM 28710 with the coccidiostats salinomycin, lasalocid,
robenidine, maduramicin, decoquinate, monensin, narasin, nicarbazin, semduramicin, diclazuril and
halofuginone at the highest authorised levels for chickens for fattening was established. Conclusions
previously drawn apply to the current application provided that the maximum authorised concentration
of the coccidiostats for turkeys for fattening, turkeys reared for breeding and minor growing poultry
species (when they exist), are equal or lower than those for chickens for fattening.
Documentation provided to EFSA
1) B-Act® (Bacillus licheniformis). August 2017. Submitted by HuvePharma NV.
2) B-Act® (Bacillus licheniformis). Supplementary information. July 2018. Submitted by
HuvePharma NV.
3) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods(s) of Analysis for B-Act®.
4) Comments from Member States.
Chronology
16/6/2017 Dossier received by EFSA
21/6/2017 Reception mandate from the European Commission
2/2/2017 Application validated by EFSA – Start of the scientiﬁc assessment
16/10/2017 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: efﬁcacy
3/7/2018 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
24/10/2018 Comments received from Member States
28/11/2018 Opinion adopted by the FEEDAP Panel. End of the Scientiﬁc assessment
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